Lee Kate E, Tu Violet Y, Faye Adam S
Department of Medicine, Duke University School of Medicine, Durham, NC, USA.
Department of Gastroenterology, New York University School of Medicine, New York, NY, USA.
Clin Exp Gastroenterol. 2024 Mar 26;17:75-86. doi: 10.2147/CEG.S359376. eCollection 2024.
Refractory Crohn's disease, defined as ongoing inflammation despite the trial of multiple advanced therapies, impacts a number of individuals with Crohn's disease, and leads to significant burden in quality of life and cost. Interventions such as early implementation of advanced therapies, optimization of current therapies prior to switching to an alternative, as well as understanding the overlapping pathophysiology between immune-mediated disorders, however, can help shift the current landscape and reduce the number of patients with refractory disease. As such, in this review we summarize the key takeaways of the latest research in the management of moderate-to-severe Crohn's disease, focusing on maximization of our currently available medications, while also exploring topics such as combination advanced therapies. We also describe evidence for emerging and alternative therapeutic modalities, including fecal microbiota transplant, exclusive enteral feeding, hyperbaric oxygen, stem cell therapy, bone marrow transplant, and posaconazole, with a focus on both the potential impact and specific indications for each.
难治性克罗恩病,定义为尽管尝试了多种先进疗法仍持续存在炎症,影响了许多克罗恩病患者,并导致生活质量和成本方面的重大负担。然而,诸如早期实施先进疗法、在改用替代疗法之前优化当前疗法以及了解免疫介导疾病之间重叠的病理生理学等干预措施,有助于改变当前局面并减少难治性疾病患者的数量。因此,在本综述中,我们总结了中重度克罗恩病管理方面最新研究的关键要点,重点是使我们目前可用的药物发挥最大效用,同时还探讨了联合先进疗法等主题。我们还描述了新兴和替代治疗方式的证据,包括粪便微生物群移植、全肠内营养、高压氧、干细胞疗法、骨髓移植和泊沙康唑,重点关注每种疗法的潜在影响和特定适应症。